Dupixent's Revenue Growth from 2019 to 2020
Dupixent (dupilumab), developed by Sanofi and Regeneron, generated $2.4 billion in global net sales in 2019. This rose to $3.6 billion in 2020, a 51% increase year-over-year, driven by expanded approvals for asthma and expansion into new markets like Europe and Japan.[1][2]
What Drove the Jump in 2020 Sales?
Stronger-than-expected uptake in moderate-to-severe asthma patients, following FDA approval in late 2018, fueled much of the growth. Patient numbers treated grew 60% to over 100,000 by year-end. Additional momentum came from chronic rhinosinusitis with nasal polyps (approved May 2020) and ongoing atopic dermatitis dominance, which accounted for about 70% of sales.[1][3]
How Did This Compare to Pre-2019 Trends?
In 2018, revenue hit $1.2 billion, showing Dupixent's rapid ramp-up from its 2017 U.S. launch for eczema. The 2019-2020 acceleration outpaced that 100% growth from 2018, reflecting maturing reimbursement and physician adoption.[1][2]
Sales Breakdown by Indication in 2020
- Atopic dermatitis: ~$2.5 billion (70%)
- Asthma: ~$900 million (25%)
- Other (nasal polyps, etc.): ~$200 million (5%)[3]
When Did Revenue Figures Get Reported?
Sanofi released full 2019 results in February 2020 and 2020 results in February 2021, both confirming these net product sales excluding U.S. Medicaid rebates.[1][2]
[1]: Sanofi 2019 Annual Results
[2]: Sanofi 2020 Annual Results
[3]: Regeneron Q4 2020 Earnings